Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). As a Key Account Director (KAD) at Madrigal, you will play a vital role in ensuring access to Rezdiffra within assigned regional Integrated Delivery Networks (IDNs) and HCP Super Groups. Working collaboratively across the matrix team, you will execute effective pull-through programs to drive the adoption of Rezdiffra and strengthen relationships with key stakeholders.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Senior
Education Level
Bachelor's degree
Number of Employees
501-1,000 employees